FLUAD FOR YOUR ELDERLY PATIENTS:

Size: px
Start display at page:

Download "FLUAD FOR YOUR ELDERLY PATIENTS:"

Transcription

1 FLUAD FOR YOUR ELDERLY PATIENTS: The first adjuvanted seasonal flu vaccine, from Novartis 1,2 FLUAD is an inactivated influenza virus vaccine indicated for active immunization against influenza in the elderly (65 years of age and older). Consistently numerically higher immune responses to tested heterovariant and homologous strains were observed for FLUAD in the elderly population and the difference was statistically significant for some strains and/or some endpoints, as compared to the comparator. The National Advisory Committee on Immunization (NACI) encourages annual vaccination for all Canadians who have no contraindication (CCDR 2009). Vaccine should be offered to the elderly up to and even after influenza virus activity is documented in a community. Comparative clinical significance is unknown.

2 INFLUENZA IN CANADA: AN OVERVIEW

3 INFLUENZA: A SIGNIFICANT BURDEN FOR ELDERLY CANADIANS Medical risk factors In older adults, the combination of immunosenescence and frequent comorbidities increases susceptibility to infection and the risk of severe outcomes 3-5 Waning immunity 3 and comorbidities (chronic disease) 4 Increased susceptibility to infection 3 Increased severity of infection 5 Increased risk of hospitalization 6 Increased mortality rate 7,8 FLUAD is not indicated to reduce complications or mortality associated with influenza.

4 UP TO 9 IN 10 DEATHS DUE TO FLU OCCUR IN THE ELDERLY 80 90% of influenza-attributable deaths occur in adults 65 years of age 7 Deaths due to influenza, pneumonia, and chronic lung disease shown to increase during influenza season (based on data) 7 Annual average of 3,484 influenza-attributable deaths ( ) 8 Elderly people are at increased risk of flu complications, especially if they have conditions like diabetes, CV or respiratory disease 9,10 FLUAD is not indicated to reduce complications or mortality associated with influenza. A study designed to examine the impact of influenza-associated respiratory illnesses on the Winnipeg health care system, including hospitalizations, physician visits and emergency room visits. Their impact on mortality was also examined. Administrative data were used to track health care use and mortality over four influenza seasons ( to ). Weekly mortality data for Canada from the to the influenza seasons were analyzed by cause of death, age group, and place of death to estimate the impact of influenza on mortality.

5 A CLOSER LOOK AT IMPACT IN THE ELDERLY Hospitalization and mortality rates due to pneumonia and influenza ( ) Rate per 1,000 people Hospitalization rate Mortality rate Adapted from Sebastian et al. 6 FLUAD is not indicated in patients under the age of 65, nor to reduce complications or mortality associated with influenza A study designed to examine associations between influenza medical visits and population-wide hospitalization/mortality due to pneumonia and influenza using administrative datasets in British Columbia, Canada. Provincial and national influenza surveillance reports were reviewed to characterize each influenza season in BC from to Data pertain to patients aged 65 years.

6 CONSIDER THE RISK OF ANTIGENIC DRIFT In the elderly, vaccine effectiveness is about half of that of healthy adults and varies depending on the outcome and the study population. 10 Antibody against one influenza virus type or subtype may confer limited or no protection against another 1 Antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype 1 Frequent development of antigenic variants through antigenic drift is the virologic basis for seasonal epidemics 1

7 FLUAD : INFLUENZA PROTECTION FOR YOUR ELDERLY PATIENTS

8 FLUAD : THE FIRST TRIVALENT, ADJUVANTED INFLUENZA VACCINE 1,2 A trivalent, surface antigen, inactivated influenza vaccine containing the three strains recommended by WHO and NACI each year: 1 A/California/7/2009 (H1N1)pdm09-like virus A/Texas/50/2012(H3N2)-like virus B/Massachusetts/2/2012-like virus FLUAD with MF59 adjuvant has been shown to increase antibody production vs. non-adjuvanted vaccine 1 FLUAD is adjuvanted with MF59, an oil-in-water emulsion composed of squalene as the oil phase, stabilized with the surfactants polysorbate 80 and sorbitan trioleate, in citrate buffer 1 FLUAD may have trace amounts of antibiotics (kanamycin, neomycin), ovalbumin, formaldehyde, CTAB (cetyltrimethylammonium bromide), or barium 1 FLUAD is an inactivated influenza virus vaccine indicated for active immunization against influenza in the elderly (65 years of age and older). Comparative clinical significance is unknown.

9 FLUAD : EFFICACY PROFILE

10 FLUAD PIVOTAL STUDY V7P17: DESIGN A randomized, comparator-controlled, observer-blind clinical study 1 Designed to support immunogenicity of FLUAD vs. the non-adjuvanted vaccine, AGRIFLU, in patients 65 years of age 1

11 FLUAD : INCREASED IMMUNE RESPONSE SHOWN VS. NON-ADJUVANTED AGRIFLU FLUAD subjects developed statistically higher antibody levels vs. non-adjuvanted AGRIFLU at day 28 (homologous strains) 1 Geometric mean titer (GMT) H3N2 H1N1 B FLUAD (n=147) AGRIFLU (n=150) 206 Adapted from Product Monograph 1 Vaccine group ratio (99.17% CI): H3N2: 1.81 ( ); H1N1: 1.38 ( ); B: 1.41 ( ) Comparative clinical significance is unknown. A randomized, comparator-controlled, observer-blind clinical study in subjects 65 years to support the immunogenicity of FLUAD compared with conventional non-adjuvanted influenza vaccine (AGRIFLU ).

12 FLUAD : NUMERICALLY OR STATISTICALLY HIGHER SEROCONVERSION RATES SHOWN VS. NON-ADJUVANTED AGRIFLU (HOMOLOGOUS STRAINS) 1 Postvaccination seroconversion at day 28 (HI assay) 1 Subjects with seroconversion/significant increase in HI titer (%) Statistically superior 55 Numerically superior Statistically superior 48 H3N2 H1N1 B 33 FLUAD (n=147) AGRIFLU (n=150) Adapted from Product Monograph 1 Vaccine group difference (99.17% CI): H3N2: 19 (4 33); H1N1: 11 (-3 25, not statistically significant); B: 16 (1 30) Comparative clinical significance is unknown.

13 FLUAD STUDY V7P3: DESIGN An immunogenicity study vs. AGRIFLU 1 Designed to analyze cross-reactivity to heterovariant influenza strains in patients aged 65 years 1

14 NUMERICALLY OR STATISTICALLY HIGHER IMMUNE RESPONSE SHOWN AGAINST ANTIGENICALLY DRIFTED STRAINS VS. NON-ADJUVANTED AGRIFLU Postvaccination circulating antibody levels (GMTs) at day 28 for heterovariant influenza strains (HI assay) 1 Numerically superior Statistically superior 300 Geometric mean titer (GMT) FLUAD (n=39) AGRIFLU (n=35) 0 H3N2 H1N1 B Adapted from Product Monograph 1 Vaccine group ratio (99.17% CI): H3N2: 1.75 ( ); H1N1: 2.03 ( ); B: 1.9 ( ) Comparative clinical significance is unknown.

15 FLUAD : SAFETY PROFILE, ADMINISTRATION AND PACKAGING

16 FLUAD : A PROVEN SAFETY PROFILE Most frequently reported adverse events in trials FLUAD (n=3,713) Comparator (n=1,656) 20 Patients (%) Injection site pain Temperature at injection site Erythema Fatigue Headache Malaise Myalgia Adapted from Product Monograph 1 Most frequently reported local and systemic events were mild to moderate and transient 3% and 1% of subjects reported a severe local or systemic reaction, respectively Local adverse events occurring within 4 days of vaccination. Systemic adverse events occurring within 4 days of vaccination.

17 FLUAD : DOSAGE AND ADMINISTRATION (ADULTS 65 YEARS OF AGE) ml intramuscularly, preferably in the region of the deltoid muscle of the upper arm (not intravascularly or subcutaneously) - FLUAD should not be injected in the gluteal region or areas where there may be a major nerve trunk FLUAD should not be mixed with other vaccines in the same syringe Separate injection limbs should be used if more than one vaccine is being administered during the same visit FLUAD should under no circumstances be administered by any other route than intramuscularly. Duration of postvaccination immunity to homologous strains or strains closely related to the vaccine varies, but is usually 6 12 months 1 Seroprotection with FLUAD is generally obtained within 2 to 3 weeks after vaccination 1.

18 FLUAD : STORAGE AND STABILITY 1 Store FLUAD between 2 and 8 C Do not freeze Do not use if vaccine has been frozen Protect from light Do not use vaccine after expiration date FLUAD can be administered following a 2-hour exposure at temperatures between 8 and 25ºC. This is not, however, a recommendation for storage

19 FLUAD : PACKAGING 1 A sterile milky-white suspension for intramuscular injection in 1 ml prefilled glass syringes containing a 0.5 ml dose The syringe plunger does not contain latex FLUAD is considered safe for use in persons with latex allergies Supplied in packages containing ten single-dose prefilled syringes

20 FLUAD : DEMONSTRATED NUMERICALLY OR STATISTICALLY SUPERIOR IMMUNE RESPONSE VS. NON-ADJUVANTED AGRIFLU FLUAD is the first and only seasonal flu vaccine coupled with the MF59 adjuvant 1 Numerically or statistically superior immunogenicity shown vs. non-adjuvanted AGRIFLU Numerically or statistically higher immune response against antigenically drifted strains shown vs. AGRIFLU Established safety profile Comparative clinical significance is unknown.

21 Indications and clinical use: FLUAD is an inactivated influenza virus vaccine indicated for active immunization against influenza in the elderly (65 years of age and older). The National Advisory Committee on Immunization (NACI) encourages annual vaccination for all Canadians who have no contraindication (CCDR 2009). Vaccine should be offered to the elderly up to and even after influenza virus activity is documented in a community. Contraindications: Hypersensitivity to the active substances, to any of the excipients and to eggs, chicken proteins, kanamycin and neomycin sulphate, formaldehyde, and cetyltrimethylammonium bromide (CTAB) Patients who have had a life-threatening reaction to previous influenza vaccination Relevant warnings and precautions: Intramuscular administration Patients with clinically significant bleeding disorders Patients with endogenous or iatrogenic immunosuppression Patients who have had Guillain-Barré syndrome within 6 weeks of receipt of prior influenza vaccine Availability of appropriate medical treatment and supervision in case of a rare anaphylactic event following administration of the vaccine Patients with febrile illness or acute infections For more information: Please consult the Product Monograph at FluadMonograph for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling the Medical Information department at References: 1. FLUAD Product Monograph. Novartis Pharmaceuticals Canada Inc., May 7, Data on file. Novartis Pharmaceuticals Canada Inc. 3. Percival SL. Ageing theories, diseases and microorganisms. In: Percival SL, editor. Microbiology and Aging. Clinical manifestations. Flintshire, UK: Humana Press; p Ohlsen K et al. Infections in the elderly. In: Percival SL, editor. Microbiology and aging: Clinical manifestations. Flintshire, UK: Humana Press; p Hayden G. Influenza in the elderly. In: Cooper JW, editor. Antivirals in the elderly. Binghamton, NY: Pharmaceutical Products Press; p Sebastian R, Skowronski DM, Chong M et al. Age-related trends in the timeliness and prediction of medical visits, hospitalizations and deaths due to pneumonia and influenza, British Columbia, Canada, Vaccine 2008;26: Menec VH, Black C, MacWilliam L and Aoki FY. The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality. Can J Public Health 2003;94: Schanzer DL, Tam TW, Langley JM and Winchester BT. Influenza-attributable deaths, Canada Epidemiol Infect 2007;135: World Health Organization. Influenza vaccines: WHO position paper. Wkly Epidemiol Rec 2005;80: Public Health Agency of Canada. Statement on seasonal influenza vaccine for CCDR August 2012;38(ACS-2):1-36. FLUAD, AGRIFLU and MF59 are registered trademarks. Product Monographs available on request. Printed in Canada Novartis Pharmaceuticals Canada Inc FLU012E

Fluzone Vaccine and Influenza Market Update

Fluzone Vaccine and Influenza Market Update Fluzone Vaccine and Influenza Market Update Jay Barber Senior Director, Marketing US Agenda 2013-2014 Fluzone Vaccine Campaign Influenza Immunization: Progress Report Sanofi Pasteur's Commitment to Influenza

More information

The Kroger Pharmacy Vaccine Administration Training Program Self-Study Quiz

The Kroger Pharmacy Vaccine Administration Training Program Self-Study Quiz The Kroger Pharmacy Vaccine Administration Training Program Self-Study Quiz Name: Date: Score: Please darken the letter on the Answer Sheet (last page) that corresponds to the correct answer, and bring

More information

Fluzone Vaccine and Influenza Market Update

Fluzone Vaccine and Influenza Market Update Fluzone Vaccine and Influenza Market Update Phil Hosbach, Vice President Immunization Policy Agenda 2012-2013 Fluzone Vaccine Campaign Influenza Immunization: Progress report Sanofi Pasteur's Commitment

More information

SEASONAL INFLUENZA VACCINE INFORMATION FOR IMMUNIZATION PROVIDERS

SEASONAL INFLUENZA VACCINE INFORMATION FOR IMMUNIZATION PROVIDERS 2015-2016 SEASONAL INFLUENZA VACCINE INFORMATION FOR IMMUNIZATION PROVIDERS Office of the Chief Medical Officer of Health Communicable Disease Control Branch Immunization Program November 2015 Table of

More information

MINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS

MINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS Government of the Republic of Trinidad and Tobago MINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS Influenza vaccines are one of the most effective ways to protect

More information

MENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals

MENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals MENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals What is Bexsero vaccine? Bexsero is a meningococcal Group B (MenB) vaccine which is indicated for the active immunisation of

More information

Sanofi Pasteur 26 Feb 2015 v0.1 372 Fluzone High-Dose LE6750

Sanofi Pasteur 26 Feb 2015 v0.1 372 Fluzone High-Dose LE6750 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Fluzone High-Dose safely and effectively. See full prescribing information for Fluzone High-Dose.

More information

The clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age.

The clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age. NAME OF THE MEDICINE TdaP-Booster. Diphtheria, tetanus and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content). DESCRIPTION TdaP-Booster is a suspension for injection in pre-filled

More information

Influenza Immunization Clinical Guidelines 2014/2015

Influenza Immunization Clinical Guidelines 2014/2015 Influenza Immunization Clinical Guidelines 2014/2015 Alberta will continue with a universal influenza immunization program (i.e., Albertans 6 months of age and older are eligible to receive provincially

More information

FAQs on Influenza A (H1N1-2009) Vaccine

FAQs on Influenza A (H1N1-2009) Vaccine FAQs on Influenza A (H1N1-2009) Vaccine 1) What is Influenza A (H1N1-2009) (swine flu) 1? Influenza A (H1N1-2009), previously known as "swine flu", is a new strain of influenza virus that spreads from

More information

2009 Novel H1N1 Influenza Vaccine Key Points

2009 Novel H1N1 Influenza Vaccine Key Points General Information 2009 Novel H1N1 Influenza Vaccine Key Points Messages: Please be patient. Vaccine will be coming. Meanwhile, use other prevention methods such as hand washing, covering coughs and sneezes,

More information

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013.

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013. The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013 Havrix 720 Junior 1 NAME OF THE MEDICINAL PRODUCT Havrix 720 Junior 2 QUALITATIVE

More information

Key Facts about Influenza (Flu) & Flu Vaccine

Key Facts about Influenza (Flu) & Flu Vaccine Key Facts about Influenza (Flu) & Flu Vaccine mouths or noses of people who are nearby. Less often, a person might also get flu by touching a surface or object that has flu virus on it and then touching

More information

Influenza Vaccine Frequently Asked Questions. Influenza Control Program

Influenza Vaccine Frequently Asked Questions. Influenza Control Program Influenza Vaccine Frequently Asked Questions Influenza Control Program Influenza or the flu can be a serious contagious disease, which is spread by droplet transmission through close contact with an infected

More information

FDA Update on the H1N1 Flu Vaccine and Antiviral Medications

FDA Update on the H1N1 Flu Vaccine and Antiviral Medications FDA Update on the H1N1 Flu Vaccine and Antiviral Medications Beth Fabian Fritsch, R.Ph., M.B.A. Commander, U.S. Public Health Service Health Programs Coordinator Office of Special Health Issues Food and

More information

See 17 for PATIENT COUNSELING INFORMATION Revised: 05/2016 FULL PRESCRIBING INFORMATION: CONTENTS*

See 17 for PATIENT COUNSELING INFORMATION Revised: 05/2016 FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use QUADRIVALENT safely and effectively. See full prescribing information for QUADRIVALENT. QUADRIVALENT

More information

BE SURE. BE SAFE. VACCINATE.

BE SURE. BE SAFE. VACCINATE. DON T GET OR GIVE THE FLU THIS YEAR THANK YOU Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2013-2014 Healthcare workers prevent the spread of flu and

More information

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2008 HAVRIX 1440

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2008 HAVRIX 1440 The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2008 HAVRIX 1440 HAVRIX 720 Junior Monodose TITLE Hepatitis A (inactivated) vaccine

More information

FOR INFORMATION CONTACT:

FOR INFORMATION CONTACT: NEWS RELEASE FOR INFORMATION CONTACT: Caroline Calderone Baisley Deborah C. Travers Director of Health Director of Family Health Tel [203] 622-7836 Tel [203] 622-7854 September 10, 2014 For Immediate Release

More information

See 17 for PATIENT COUNSELING INFORMATION. Revised: November 2009

See 17 for PATIENT COUNSELING INFORMATION. Revised: November 2009 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Influenza A (H1N1) 2009 Monovalent Vaccine safely and effectively. See full prescribing information

More information

Vaccination is the only protection. BE SURE. BE SAFE. VACCINATE.

Vaccination is the only protection.  BE SURE. BE SAFE. VACCINATE. Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2011-2012 INFORMATION FOR PREGNANT WOMEN What is seasonal flu (influenza)? Seasonal flu is a highly infectious

More information

Retail Pharmacy Presentation Pharmacist Market Research Insights 2H2013

Retail Pharmacy Presentation Pharmacist Market Research Insights 2H2013 Retail Pharmacy Presentation Pharmacist Market Research Insights 2H2013 Overview of the Pharmacy Market Research Patients in the US are increasingly turning to the retail pharmacy for their preventive

More information

Medicago overview. Update on plant-made VLPs. Influenza virus-like particle production in plants. Transient expression in N.

Medicago overview. Update on plant-made VLPs. Influenza virus-like particle production in plants. Transient expression in N. Medicago overview Focus Vaccines & Proteinbased pharmaceuticals Update on plantmade VLPs Manufacturing technology Transient expression in tobacco Vaccine technology Viruslike particles Employees 240 Headquarters,

More information

FLUARIX PRODUCT INFORMATION (Inactivated Split Influenza Vaccine)

FLUARIX PRODUCT INFORMATION (Inactivated Split Influenza Vaccine) FLUARIX PRODUCT INFORMATION (Inactivated Split Influenza Vaccine) NAME OF THE MEDICINE Fluarix inactivated split influenza vaccine suspension for injection DESCRIPTION Fluarix is an inactivated and purified

More information

Annual Residential Care Update Influenza

Annual Residential Care Update Influenza Annual Residential Care Update Influenza 2014-2015 VCH Communicable Disease Control 1 Slides will be available by mid-october on the VCH Internet (www.vch.ca) 2 1 New online course For immunizers who are

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT FSME-IMMUN 0.25 ml Junior Suspension for injection in pre-filled syringe Tick-Borne Encephalitis Vaccine (Inactivated) 2. QUALITATIVE

More information

History and epidemiology of the disease. The disease

History and epidemiology of the disease. The disease 20 The disease (JE) is a mosquito-borne viral caused by a flavivirus. It is the leading cause of childhood in Asia, with 20,000 to 50,000 cases per annum (Halstead et al., 2008; World Health Organization,

More information

Medication Protocol for the Administration of Inactivated Influenza Vaccine (Split Virion) BP Version 1, September 2015

Medication Protocol for the Administration of Inactivated Influenza Vaccine (Split Virion) BP Version 1, September 2015 Medication Protocol for the Administration of Inactivated Influenza Vaccine (Split Virion) BP to nurses, midwives and Healthcare Workers by registered nurses and registered midwives This medication protocol

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS Registration No. : 2C 22/47 (N) Importer / Manufacturer: Sanofi Pasteur Ltd., Thailand/Sanofi Pasteur S.A., France SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT : PENTAXIM (Diphtheria,

More information

Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com

Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com News Release FOR IMMEDIATE RELEASE Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com Merck's HPV Vaccine, GARDASIL 9, now available

More information

2. What is the frequency of repeat TDAP? At this point, patients only need 1 Tdap dose during their lifetime.

2. What is the frequency of repeat TDAP? At this point, patients only need 1 Tdap dose during their lifetime. Questions & Answers from Immunization Update 2012 Live Webinar Session 8/29/12 1. Is there a safety cap on the plunger of the intradermal flu syringe? The Fluzone Intradermal injection device has a needle

More information

AV1300 STAFF INFLUENZA IMMUNIZATION AND EXCLUSION POLICY

AV1300 STAFF INFLUENZA IMMUNIZATION AND EXCLUSION POLICY AV1300 STAFF INFLUENZA IMMUNIZATION AND EXCLUSION POLICY 1.0 PURPOSE To help ensure that those at greatest risk of complications and death from influenza are optimally protected through the appropriate

More information

H1N1 Flu Vaccine Available to All Virginia Beach City Public Schools Students

H1N1 Flu Vaccine Available to All Virginia Beach City Public Schools Students V i r g i n i a B e a c h C i t y P u b l i c S c h o o l s apple-a-day F o r O u r F a m i l y o f I n t e r e s t e d C i t i z e n s Special Edition H1N1 Flu Vaccine Available to All Virginia Beach

More information

Varicella and Varicella Vaccine

Varicella and Varicella Vaccine Varicella and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp

More information

Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1)

Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) This Influenza Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses (

More information

Giving Flu Shots to Egg Allergic Children. Disclosure Information. Objective. Influenza vaccination of eggallergic

Giving Flu Shots to Egg Allergic Children. Disclosure Information. Objective. Influenza vaccination of eggallergic Giving Flu Shots to Egg Allergic Children John M Kelso, MD Division of Allergy, Asthma and Immunology Scripps Clinic San Diego CA Clinical Professor of Pediatrics University of California, San Diego School

More information

SWINE FLU AND PREGNANCY

SWINE FLU AND PREGNANCY SWINE FLU AND PREGNANCY How to protect yourself and your baby This leaflet gives information about: Flu. Protect yourself and others. SWINE FLU AND PREGNANCY Contents What is swine flu? Swine flu is a

More information

Hepatitis A Vaccine Biological Page

Hepatitis A Vaccine Biological Page Hepatitis A Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.230 Created by: Province-wide Immunization Program Standards and Quality Approved by: Province-wide Immunization

More information

SWINE FLU VACCINATION:

SWINE FLU VACCINATION: SWINE FLU VACCINATION: information for parents of children over six months and under five years old Flu. Protect yourself and others. Contents About this leaflet......................... 3 What is swine

More information

swine flu vaccination:

swine flu vaccination: swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?............... 3 About the swine flu vaccine....... 4 What else do I need to know?...... 8 What

More information

Chapter 8. Vaccine Administration

Chapter 8. Vaccine Administration Chapter 8 Vaccine Administration 8.1 Objectives To understand how to prepare vaccines for immunisation To understand how to administer vaccines To understand what are true contraindications for vaccine

More information

PRODUCT MONOGRAPH D INFLUVAC. influenza vaccine, surface antigen, inactivated. Suspension for Injection

PRODUCT MONOGRAPH D INFLUVAC. influenza vaccine, surface antigen, inactivated. Suspension for Injection PRODUCT MONOGRAPH D INFLUVAC influenza vaccine, surface antigen, inactivated Suspension for Injection Each 0.5 ml pre-filled syringe contains neuraminidase and 15 mcg hemagglutinin of each virus strain

More information

Anaphylaxis and other adverse events

Anaphylaxis and other adverse events Anaphylaxis and other adverse events Aim: To be able to manage anaphylaxis and other adverse events correctly Learning outcomes Define local and systemic adverse events Distinguish between anaphylaxis

More information

Vaccination during pregnancy protects both mother and unborn child.

Vaccination during pregnancy protects both mother and unborn child. Grippeimpfung (Englisch) Schwangere Information for expectant mothers Flu Vaccination Vaccination during pregnancy protects both mother and unborn child. Staying healthy during pregnancy During pregnancy,

More information

ALBERTA IMMUNIZATION POLICY GUIDELINES

ALBERTA IMMUNIZATION POLICY GUIDELINES ALBERTA IMMUNIZATION POLICY GUIDELINES Diphtheria, Tetanus, Pertussis, Polio and Hib Vaccines. Diphtheria-Tetanus-Acellular Pertussis-Polio-Haemophilus influenzae type b Conjugate Combined Vaccine (DTaP-IPV-

More information

Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for registered healthcare practitioners

Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for registered healthcare practitioners Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for registered healthcare practitioners Questions and Answers May 2014 Health Protection Scotland

More information

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works. November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also

More information

OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV)

OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV) OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Human Papilloma Virus Vaccines (HPV) Revisions as of 01-01-2016 Vaccination age changed to clients 7 years of age Removal of adolescent well

More information

Indicated for flu treatment for ages 2 weeks and older

Indicated for flu treatment for ages 2 weeks and older DOSAGE AND ADMINISTRATION IN ADULT AND PEDIATRIC PATIENTS Please see Important Safety Information on pages 6 8. Indicated for flu treatment for ages 2 weeks and older Available in 30-mg, 45-mg, and 75-mg

More information

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 4 CONTRAINDICATIONS

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 4 CONTRAINDICATIONS HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Fluzone Quadrivalent safely and effectively. See full prescribing information for Fluzone Quadrivalent.

More information

Routine Immunization Products

Routine Immunization Products Newfoundland and Labrador Immunization Manual Section 3 Routine Immunization Products Immunization with Diphtheria, Pertussis, Tetanus, Polio and Hib vaccine (DTaP-IPV- Hib) 3.1-1 Immunization with Diphtheria,Tetanus,Pertussis

More information

SEASONAL FLU VACCINATION: WHO SHOULD HAVE IT AND WHY

SEASONAL FLU VACCINATION: WHO SHOULD HAVE IT AND WHY SEASONAL FLU VACCINATION: WHO SHOULD HAVE IT AND WHY This leaflet includes information for pregnant women INTRODUCTION Last year you probably heard a great deal about different sorts of flu, including

More information

Healthcare Personnel Influenza Immunization Policy

Healthcare Personnel Influenza Immunization Policy Influenza FAQ Healthcare Personnel Influenza Immunization Policy The seasonal influenza (flu) vaccine is now recommended for most people ages 6 months and older. All designated personnel at Washington

More information

Vaccine Protocol Agreement. Name of Pharmacy: Address: City, State, Zip:

Vaccine Protocol Agreement. Name of Pharmacy: Address: City, State, Zip: Vaccine Protocol Agreement Name of Pharmacy: Address: City, State, Zip: This Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses ( Nurses

More information

INFLUENZA IMMUNIZATION OF REGISTERED NURSES

INFLUENZA IMMUNIZATION OF REGISTERED NURSES INFLUENZA IMMUNIZATION OF REGISTERED NURSES CNA POSITION CNA recognizes that influenza is a serious illness that affects certain populations disproportionately. Vulnerable groups, such as infants, seniors,

More information

2013-2014. Live Attenuated Influenza Vaccine Questions and Answers for Health Care Providers

2013-2014. Live Attenuated Influenza Vaccine Questions and Answers for Health Care Providers 2013-2014 Live Attenuated Influenza Vaccine Questions and Answers for Health Care Providers BACKGROUND... 5 1. What is live attenuated influenza vaccine (LAIV)?... 5 2. Why is LAIV an intranasal spray?...

More information

ALBERTA IMMUNIZATION POLICY GUIDELINES

ALBERTA IMMUNIZATION POLICY GUIDELINES ALBERTA IMMUNIZATION POLICY GUIDELINES Hepatitis Vaccines. Hepatitis A Vaccines Refer to the vaccine product monograph and the Canadian Immunization Guide for further Product monographs are available on

More information

FLU VACCINATION - FREQUENTLY ASKED QUESTIONS

FLU VACCINATION - FREQUENTLY ASKED QUESTIONS FLU VACCINATION - FREQUENTLY ASKED QUESTIONS SEASONAL FLU VACCINATION 2015 2016 As a health care worker, am I required to be vaccinated against influenza (the flu)? It is not mandatory to be vaccinated

More information

NHS FORTH VALLEY. Administration of VZIG in close contact with chicken pox or shingles in a pregnant woman. Unit Clinical Governance

NHS FORTH VALLEY. Administration of VZIG in close contact with chicken pox or shingles in a pregnant woman. Unit Clinical Governance NHS FORTH VALLEY Date of First Issue 01/04/2006 Approved 05/05/2012 Current Issue Date 18/09/2012 Review Date 18/09/2016 Version 1.2 EQIA Yes 01/04/2012 Author / Contact Group Committee Final Approval

More information

Immunization Healthcare Branch. Meningococcal Vaccination Program Questions and Answers. Prepared by

Immunization Healthcare Branch. Meningococcal Vaccination Program Questions and Answers. Prepared by Immunization Healthcare Branch Meningococcal Vaccination Program Questions and Answers Prepared by Immunization Healthcare Branch (IHB), Defense Health Agency Last Updated: 27 Mar 06 www.vaccines.mil 877-GET-VACC

More information

Influenza - H1N1 Vaccination Program Questions and Answers. Prepared by

Influenza - H1N1 Vaccination Program Questions and Answers. Prepared by Influenza - H1N1 Vaccination Program Questions and Answers Prepared by Military Vaccine (MILVAX) Agency, Office of The Army Surgeon General, U.S. Army Last Updated: 27 Oct 09 www.vaccines.mil 877-GET-VACC

More information

Seasonal Influenza (Flu) Questions and Answers For Healthcare Providers

Seasonal Influenza (Flu) Questions and Answers For Healthcare Providers Seasonal Influenza (Flu) Questions and Answers For Healthcare Providers 1/11/2013 1:50 PM 1 Contents Vaccine... 3 Testing... 5 Surveillance... 6 Antivirals... 7 Infection Control... 10 1/11/2013 1:50 PM

More information

X-Plain H1N1 Flu (Swine Flu) Reference Summary

X-Plain H1N1 Flu (Swine Flu) Reference Summary X-Plain H1N1 Flu (Swine Flu) Reference Summary Introduction H1N1 flu, also called swine flu, is a respiratory disease of pigs that has now spread to humans. Swine refers to animals such as pigs, hogs,

More information

Emerging Drug List VACCINES FOR AVIAN INFLUENZA

Emerging Drug List VACCINES FOR AVIAN INFLUENZA Generic (Trade Name): Influenza A/H5N1 prototype vaccine NO. 70 JANUARY 2006 Manufacturer: Indication: Current Regulatory Status: Description: Vaccines are being developed by Chiron Corporation (Emeryville

More information

TdaP-Booster (tee-dee-ay-pee boo-ster)

TdaP-Booster (tee-dee-ay-pee boo-ster) New Zealand Consumer Medicine Information TdaP-Booster (tee-dee-ay-pee boo-ster) Tetanus, diphtheria and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content) CONSUMER MEDICINE

More information

Factsheet September 2012. Pertussis immunisation for pregnant women. Introduction

Factsheet September 2012. Pertussis immunisation for pregnant women. Introduction Factsheet September 2012 Pertussis immunisation for pregnant women Introduction The routine childhood immunisation programme has been very effective in reducing the overall numbers of cases of pertussis.

More information

TdaPBooster. Tetanus, diphtheria and pertussis vaccination of children, adolescents and adults throughout life

TdaPBooster. Tetanus, diphtheria and pertussis vaccination of children, adolescents and adults throughout life TdaPBooster Tetanus, diphtheria and pertussis vaccination of children, adolescents and adults throughout life CONTENTS Statens Serum Institut vaccine production Pertussis in Denmark Pertussis vaccination

More information

The flu vaccination. Winter 2013/14. Who should have it and why. Includes information for pregnant women

The flu vaccination. Winter 2013/14. Who should have it and why. Includes information for pregnant women The flu vaccination Winter 2013/14 Who should have it and why Includes information for pregnant women Introduction This leaflet explains how you can protect yourself against flu this coming winter, and

More information

Immunization Information for Blinn College Students

Immunization Information for Blinn College Students 1 Immunization Information for Blinn College Students *Important Information Regarding the Bacterial Meningitis Vaccine* The State passed Senate Bill 1107 in 2011 and recently Senate Bill 62 in 2013, which

More information

PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM 197 Protein]) Suspension for intramuscular injection Initial US Approval: 2010

PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM 197 Protein]) Suspension for intramuscular injection Initial US Approval: 2010 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PREVNAR 13 safely and effectively. See full prescribing information for PREVNAR 13. PREVNAR 13 (Pneumococcal

More information

Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS

Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS Registration No. 1C 68/47(NC) Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT VARIVAX [Varicella

More information

NHS FORTH VALLEY. Varicella Care Pathway for GPs

NHS FORTH VALLEY. Varicella Care Pathway for GPs NHS FORTH VALLEY Date of First Issue 01/04/2006 Approved 05/05/2012 Current Issue Date 28/04/2014 Review Date 28/04/2016 Version 1.2 EQIA Yes 01/04/2012 Author / Contact Debbie Forbes Group Committee Unit

More information

Influenza Education Presentation Prepared by Peel Public Health 2014

Influenza Education Presentation Prepared by Peel Public Health 2014 Influenza Education Presentation Prepared by Peel Public Health 2014 Disclaimer We are pleased to be able to offer you the use of our Influenza PowerPoint presentation for your use. Peel Public Health

More information

Pandemic influenza A(H1N1)v vaccines authorised via the core dossier procedure

Pandemic influenza A(H1N1)v vaccines authorised via the core dossier procedure European Medicines Agency London, 24 September 2009 Doc.Ref.: EMEA/608259/2009 rev. * Pandemic influenza A(H1N1)v vaccines authorised via the core dossier procedure Explanatory note on scientific considerations

More information

If you have any concerns about being given this vaccine, ask your doctor or pharmacist.

If you have any concerns about being given this vaccine, ask your doctor or pharmacist. PNEUMOVAX 23 Pneumococcal Vaccine Single Dose Vial/Pre-filled Syringe What is in this leaflet This leaflet answers some common questions about PNEUMOVAX 23. It does not contain all the available information.

More information

John M. Kelso, MD, James T. Li, MD, PhD, and Matthew J. Greenhawt, MD, MBA

John M. Kelso, MD, James T. Li, MD, PhD, and Matthew J. Greenhawt, MD, MBA 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 Update on Egg Allergy and Influenza Vaccine (Nov 2011) John M. Kelso, MD, James T. Li, MD,

More information

LEGISLATIVE COUNCIL BRIEF. Prevention and Control of Disease Ordinance (14 of 2008)

LEGISLATIVE COUNCIL BRIEF. Prevention and Control of Disease Ordinance (14 of 2008) LEGISLATIVE COUNCIL BRIEF Prevention and Control of Disease Ordinance (14 of 2008) PREVENTION AND CONTROL OF DISEASE ORDINANCE (AMENDMENT OF SCHEDULE 1) (NO.2) NOTICE 2009 PREVENTION AND CONTROL OF DISEASE

More information

H1N1 SWINE FLU PANDEMIC

H1N1 SWINE FLU PANDEMIC H1N1 SWINE FLU PANDEMIC 2 PANDEMIC H1N1 SWINE FLU Pandemic H1N1 Swine flu A novel influenza A H1N1 virus emerged from Mexico in April 2009 and spread so rapidly that the World Health Organisation declared

More information

Illinois Long Term Care Facilities and Assisted Living Facilities

Illinois Long Term Care Facilities and Assisted Living Facilities TO: FROM: RE: Illinois Long Term Care Facilities and Assisted Living Facilities Richard Dees, Chief, Bureau of Long Term Care Karen McMahon, Immunization Section Chief Craig Conover, MD, Medical Director,

More information

Polio and the Introduction of IPV

Polio and the Introduction of IPV Polio and the Introduction of IPV Poliomyelitis (polio) is a highly infectious disease that is caused when a person is infected by the polio virus that invades the nervous system. Poliomyelitis can cause

More information

LARGE PRINT VERSION. PRINT A4 SIZE (TEXT >16pt) PREGNANT? LUNG DISEASE? HEART DISEASE? CANCER? OBESITY? DIABETES? LONG-TERM ILLNESS?

LARGE PRINT VERSION. PRINT A4 SIZE (TEXT >16pt) PREGNANT? LUNG DISEASE? HEART DISEASE? CANCER? OBESITY? DIABETES? LONG-TERM ILLNESS? LARGE PRINT VERSION. PRINT A4 SIZE (TEXT >16pt) PREGNANT? LUNG DISEASE? HEART DISEASE? CANCER? OBESITY? DIABETES? LONG-TERM ILLNESS? SWINE IT STOPS FOR YOU Getting the Swine Flu vaccine will protect you

More information

GlaxoSmithKline Pandemic Influenza Portfolio

GlaxoSmithKline Pandemic Influenza Portfolio GlaxoSmithKline Pandemic Influenza Portfolio Schladminger Gesundheitsgespräche 06. June 2009 Responding to the Pandemic Influenza Threat - WHO Recommended Strategic Actions Non-pharmacological measures

More information

Mini Guide to Flu & Flu Vaccines

Mini Guide to Flu & Flu Vaccines Mini Guide to Flu & Flu Vaccines This Mini Guide is Your Free Gift from Mercola.com as a thank you for helping us support the National Vaccine Information Center (NVIC). With every order during Vaccine

More information

Seasonal Flu Basics. Flu Season is Usually fall through early spring, but you can get the flu at any time of the year

Seasonal Flu Basics. Flu Season is Usually fall through early spring, but you can get the flu at any time of the year Seasonal Flu Basics Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. It spreads from person-to-person and can cause mild to severe illness; and in

More information

PRODUCT MONOGRAPH FLUVIRAL (2015-2016)

PRODUCT MONOGRAPH FLUVIRAL (2015-2016) PRODUCT MONOGRAPH FLUVIRAL 2015-2016 Trivalent Influenza Vaccine (Split Virion, Inactivated) Suspension for Injection ATC Code J07BB02 Manufactured by: ID Biomedical Corporation of Quebec Quebec, Quebec

More information

Immunizing Pharmacist Signature

Immunizing Pharmacist Signature OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS Yellow Fever 1 01-2016 Vaccination age changed to clients 7 years of age Removal of the Adolescent Well Visit Flyer I. Oregon Immunization

More information

Excess mortality in Europe in the winter season 2014/15, in particular amongst the elderly.

Excess mortality in Europe in the winter season 2014/15, in particular amongst the elderly. Excess mortality in Europe in the winter season 2014/15, in particular amongst the elderly. An analysis of all-cause mortality from 15 European countries participating in the EuroMOMO network (www.euromomo.eu)

More information

HAVRIX (Hepatitis A Vaccine, Inactivated)

HAVRIX (Hepatitis A Vaccine, Inactivated) HAVRIX (Hepatitis A Vaccine, Inactivated) PRESCRIBING INFORMATION DESCRIPTION HAVRIX (Hepatitis A Vaccine, Inactivated) is a noninfectious hepatitis A vaccine developed and manufactured by GlaxoSmithKline

More information

SWINE FLU: FROM CONTAINMENT TO TREATMENT

SWINE FLU: FROM CONTAINMENT TO TREATMENT SWINE FLU: FROM CONTAINMENT TO TREATMENT SWINE FLU: FROM CONTAINMENT TO TREATMENT INTRODUCTION As Swine Flu spreads and more people start to catch it, it makes sense to move from intensive efforts to contain

More information

PRIMARY CARE PRACTICE GUIDELINES

PRIMARY CARE PRACTICE GUIDELINES 1 of 6 1. OUTCOME To identify anaphylaxis in the primary care setting and provide an evidence informed emergency response utilizing the most current provincial and federal practice guidelines. 2. DEFINITIONS

More information

The Manitoba Seasonal Influenza Immunization Program Plan 2015-16

The Manitoba Seasonal Influenza Immunization Program Plan 2015-16 The Manitoba Seasonal Influenza Immunization Program Plan 2015-16 Interim Plan June 2015 Public Health Branch Public Health and Primary Health Care Division Manitoba Health, Healthy Living and Seniors

More information

Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System

Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System Ontario Public Drug Programs, Ministry of Health and Long-Term Care Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System For the 2012-2013

More information

Facts About Chickenpox and Shingles for Adults

Facts About Chickenpox and Shingles for Adults Facts About Chickenpox and Shingles for Adults What is chickenpox? Chickenpox, also known as varicella, is a very contagious disease caused by the varicella-zoster virus. It is spread easily through the

More information

160S01105, Page 1 of 7. Human Hepatitis B Immunoglobulin, solution for intramuscular injection.

160S01105, Page 1 of 7. Human Hepatitis B Immunoglobulin, solution for intramuscular injection. 160S01105, Page 1 of 7 New Zealand Data Sheet Hepatitis B Immunoglobulin-VF NAME OF THE MEDICINE Human Hepatitis B Immunoglobulin, solution for intramuscular injection. DESCRIPTION Hepatitis B Immunoglobulin-VF

More information

Overview of Vaccine Efficacy and Vaccine Effectiveness

Overview of Vaccine Efficacy and Vaccine Effectiveness Overview of Vaccine Efficacy and Vaccine Effectiveness Shelly McNeil, MD Canadian Center for Vaccinology Dalhousie University Halifax, Nova Scotia Canada Efficacy vs Effectiveness Vaccine efficacy- % reduction

More information

Fluzone Vaccine and Influenza Market Update. Bill Averbeck, AVP Marketing

Fluzone Vaccine and Influenza Market Update. Bill Averbeck, AVP Marketing Fluzone Vaccine and Influenza Market Update Bill Averbeck, AVP Marketing Agenda 2010 Fluzone Vaccine Campaign Influenza Disease Update and Vaccination Recommendations Sanofi Pasteur's Commitment to Driving

More information

I B2.4. Design of the patient information leaflet for VariQuin

I B2.4. Design of the patient information leaflet for VariQuin (English translation of official Dutch version) I B2.4. Design of the patient information leaflet for VariQuin Information for the Patient: Read this package leaflet carefully when you have some time to

More information

New York State Department of Health Immunization Program Combined Hepatitis A and B Vaccine Dosing Schedule Policy

New York State Department of Health Immunization Program Combined Hepatitis A and B Vaccine Dosing Schedule Policy New York State Department of Health Immunization Program Combined Hepatitis A and B Vaccine Dosing Schedule Policy Policy Statement The accelerated four-dose schedule for combined hepatitis A and B vaccine

More information

Document Title: PCT Doc Ref.: Version No.: 1/2014. Local Doc Ref.:

Document Title: PCT Doc Ref.: Version No.: 1/2014. Local Doc Ref.: Document Title: Patient Group Direction (PGD) for the vaccination of pregnant women (gestation week 28 onwards) and new mothers against pertussis (Whooping Cough) using Boostrix-IPV (Diphtheria, tetanus,

More information